NovoLog insulin aspart approved for pediatric use

Article

The Food and Drug Administration approved the NovoLog insulin pump in pediatric patients, aged 4 to 18.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!
Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Related Content
© Contemporary Pediatrics

FDA news in pediatrics: June 2025

Morgan Ebert, Managing Editor
July 1st 2025
Article

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from June 2025.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
MNV-201 receives fast track, rare pediatric disease to treat Pearson Syndrome | Image Credit: © John Doe - © John Doe - stock.adobe.com.

MNV-201 receives fast track, rare pediatric disease to treat Pearson Syndrome

Joshua Fitch, Senior Editor
June 30th 2025
Article

MNV-201 is being evaluated in phase 2 clinical trials for treatment of the ultra-rare, life-threatening mitochondrial disorder affecting children.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
Weekly review: ACIP meets and votes, marstacimab data for hemophilia, and more | Image Credit: © Artur - © Artur - stock.adobe.com.

Weekly review: ACIP meets and votes, marstacimab data for hemophilia, and more

Joshua Fitch, Senior Editor
June 27th 2025
Article

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis

Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis

Mercedes E. Gonzalez, MD
June 27th 2025
Article

Roflumilast cream 0.05% is being studied for mild-to-moderate AD in infants aged 3 months to under 2 years in a new phase 2 trial.

© 2025 MJH Life Sciences

All rights reserved.